 | CUTANEOUS T CELL LYMPHOMA: BASIC AND CLINICALLY RELEVANT BIOLOGY
Copyright © 2001 by the New York Academy of Sciences
description
Annals of the New York Academy of Sciences 941:177-184 (2001)
© 2001 New York Academy of Sciences
The Role for Interleukin-12 Therapy of Cutaneous T Cell Lymphoma
ALAIN H. ROOK,
MOHAMED H. ZAKI,
MARIA WYSOCKA,
GARY S. WOOD,
MADELEINE DUVIC,
LOUISE C. SHOWE,
FRANCINE FOSS,
MICHAEL SHAPIRO,
TIMOTHY M. KUZEL,
ELISE A. OLSEN,
ERIC C. VONDERHEID,
ROBERT LALIBERTE AND
MATTHEW L. SHERMAN
Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Address for correspondence: Alain H. Rook, M.D., Department of Dermatology, University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19104. Voice: 215-662-6751; fax: 215-615-0016.
arook{at}mail.med.upenn.edu
Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8 + and/or TIA-1 + T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.
Key Words: recombinant human interleukin-12 • interferon-  • interleukin-2
This article has been cited by other articles:
|
|
|
|
 
M. Nebozhyn, A. Loboda, L. Kari, A. H. Rook, E. C. Vonderheid, S. Lessin, C. Berger, R. Edelson, C. Nichols, M. Yousef, et al.
Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy
Blood,
April 15, 2006;
107(8):
3189 - 3196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. T. Rosen and C. Querfeld
Primary Cutaneous T-Cell Lymphomas
Hematology,
January 1, 2006;
2006(1):
323 - 330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mitsuhashi, J. Liu, S. Cao, X. Shi, and X. Ma
Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas
J. Leukoc. Biol.,
August 1, 2004;
76(2):
322 - 332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Shi, S. Cao, M. Mitsuhashi, Z. Xiang, and X. Ma
Genome-Wide Analysis of Molecular Changes in IL-12-Induced Control of Mammary Carcinoma via IFN-{gamma}-Independent Mechanisms
J. Immunol.,
April 1, 2004;
172(7):
4111 - 4122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Maier, A. Tun-Kyi, A. Tassis, K.-P. Jungius, G. Burg, R. Dummer, and F. O. Nestle
Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells
Blood,
October 1, 2003;
102(7):
2338 - 2344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Velupillai, J. P. Carroll, and T. L. Benjamin
Susceptibility to Polyomavirus-Induced Tumors in Inbred Mice: Role of Innate Immune Responses
J. Virol.,
August 28, 2002;
76(19):
9657 - 9663.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Connors, E. D. Hsi, and F. M. Foss
Lymphoma of the Skin
Hematology,
January 1, 2002;
2002(1):
263 - 282.
[Abstract]
[Full Text]
|
|
|
|
